Factors influencing the cellular accumulation of SN-38 and camptothecin

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 3, 2002, Pages 194-200

  Cummings, Jeffrey ^a   Boyd, Gary ^a   Macpherson, Janet S ^a   Wolf, Helga ^b   Smith, Gillian ^b   Smyth, John F ^a   Jodrell, Duncan I ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Camptothecin; Cellular accumulation; Chemical stability; Glucuronidation; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; GLYCOPROTEIN P; HYDROXYACID; LACTONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; RNA;

ARTICLE; BIOPHYSICS; CANCER CELL; CATALYSIS; CELL STRAIN HT29; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DEGRADATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; OVARY CELL CULTURE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; FEMALE; GENES, MDR; HUMANS; KINETICS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036189275     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0393-3     Document Type: Article

References (46)

1. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous media
2. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
3. High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells
4. ATP-dependent efflux of CPT-11 and SN38 by the multidrug resistance protein (MRP) and its inhibition by Pak-104P
5. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
6. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
7. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
8. Glucuronidation as a de novo mechanism of drug resistance in colon cancer cells
9. Novel mechanism of drug resistance to the topoisomerase I (topo I) inhibitor NU/ICRF 505
10. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug sensitive and drug resistant human ovarian cancer cell lines determined by HPLC
11. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
12. Molecular modelling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin
13. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues
14. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH
15. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development
16. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s)
17. Inactivation of p53 increases the cytoxicity of camptothecin in human colon HCTll6 and breast MCF-7 cells
18. Differential cytotoxicity of clinically important camptothecin derivatives in p-glycoprotein-overexpressing cell lines
19. Effects of camptothecin on the breakage and repair of DNA during the cell cycle
20. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
21. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
22. Structure activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
23. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
24. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance
25. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
26. pH-Dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
27. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells
28. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells
29. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cells
30. MRP3, an organic anion transporter able to transport anti-cancer drugs
31. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines
32. Reduced cellular accumulation of topotecan - A novel mechanism of resistance in a human ovarian cancer cell line
33. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the eamptothecin family: Their possible role in the unique mode of drug action
34. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
35. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantroen-selected cell lines
36. Topoisomerase I inhibitors in the treatment of colorectal cancer
37. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
38. New directions in the treatment of colorectal cancer: A look to the future
39. Tumour necrosis factor α and expression of the multidrug resistance-associated genes LRP and MRP
40. A model for the mechanism of human topoisomerase I
41. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro
42. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydroehloride (CPT-11) in rats
43. Schedule-dependent eytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
44. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers
45. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells